New CAR T-Cell therapy targets Hard-to-Treat brain tumors
NCT ID NCT05627323
First seen Jan 30, 2026 · Last updated May 21, 2026 · Updated 16 times
Summary
This early-stage study tests a new treatment called CHM-1101 for people with a fast-growing brain cancer (glioblastoma) that has returned or worsened. The therapy uses specially engineered immune cells (CAR T-cells) designed to find and attack cancer cells carrying a marker called MMP2. The main goals are to check safety, find the best dose, and see if it helps shrink tumors. About 42 adults with this type of brain cancer will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA MULTIFORME OF BRAIN are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
-
St. David's South Austin Medical Center - Sarah Cannon - Austin
Austin, Texas, 78704, United States
Conditions
Explore the condition pages connected to this study.